Penumbra, Inc. (PEN)

Market Cap	12.52B +11.9%
Revenue (ttm)	1.45B +17.3%
Net Income	171.05M +305.0%
EPS	4.34 +302.4%
Shares Out	39.33M
PE Ratio	73.47
Forward PE	59.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	185,431
Open	318.41
Previous Close	318.30
Day's Range	317.81 - 320.75
52-Week Range	221.26 - 362.41
Beta	0.74
Analysts	Hold
Price Target	363.36 (+14.15%)
Earnings Date	May 6, 2026

About PEN

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron ...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 18, 2015
• Employees: 4,700
• Stock Exchange: NYSE
• Ticker Symbol: PEN
• Website: https://www.penumbrainc.com

Financial Performance

In 2025, Penumbra's revenue was $1.40 billion, an increase of 17.50% compared to the previous year's $1.19 billion. Earnings were $177.69 million, an increase of 1168.11%.

Analyst Summary

According to 17 analysts, the average rating for PEN stock is "Hold." The 12-month stock price target is $363.36, which is an increase of 14.15% from the latest price.

Price Target

$363.36

(14.15% upside)

Analyst Consensus: Hold